Wedbush lowered the firm’s price target on Alto Neuroscience (ANRO) to $21 from $22 and keeps a Neutral rating on the shares after the company reported top-line results from its Phase 2 proof-of-concept study of ALTO-101 in cognitive impairment in schizophrenia. The firm notes study did not meet the primary EEG or cognitive endpoints in the study with the EEG theta band effect just missing significance. Wedbush is removing the ALTO-101 program from its estimates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Morning Movers: Immunovant sinks after batoclimab trials miss goal
- Alto Neuroscience price target lowered to $38 from $41 at Baird
- Alto Neuroscience price target lowered to $44 from $49 at JonesResearch
- Closing Bell Movers: Globalstar spikes on acquisition report
- Alto Shifts Focus to ALTO-207 After ALTO-101 Data